<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLUOCINONIDE- fluocinonide solution </strong><br>Actavis Mid Atlantic LLC<br></p></div>
<h1><span class="Bold">FLUOCINONIDE TOPICAL SOLUTION, USP 0.05%</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bf0d6976-a855-4a09-af87-bdc1a9fc439a"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_13f43a46-2f34-48df-af0d-a075c283c8b5"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION
</span></h1>
<p class="First">The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and anti-pruritic agents. The steroids in this class include fluocinonide. Fluocinonide is designated chemically as: pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene) bis(oxy)]-,(6α, 11ß, 16α)-. It has the following structural formula:</p>
<div class="Figure"><img alt="152f1db7-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=edb61362-d48f-487a-b15f-5ea3089d2f30&amp;name=fluocinonide-topical-solution-1.jpg"></div>
<p> C<span class="Sub">26</span>H<span class="Sub">32</span>F<span class="Sub">2</span>O<span class="Sub">7</span>                   494.53</p>
<p>Fluocinonide Topical Solution contains fluocinonide 0.5 mg/mL in a solution of alcohol (35%), diisopropyl adipate, citric acid and propylene glycol. In this formulation, the active ingredient is totally in solution.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_9993d5b9-d4ff-4701-8bc8-d8a1a51ec73c"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY
</span></h1>
<p class="First">Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions.</p>
<p>The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_b06a5a03-f371-40dc-a2b6-ae5cec56028a"></a><a name="section-3.1"></a><p></p>
<h2><span class="Bold">Pharmacokinetics
</span></h2>
<p class="First">The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. A significantly greater amount of fluocinonide is absorbed from the solution than from the cream or gel formulations.</p>
<p>Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See <a href="#LINK_ce186c82-d576-4309-9d52-1febb1cb12a2">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_77d71844-f010-46ad-8802-0cb1cd96b09c"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE
</span></h1>
<p class="First">Fluocinonide topical solution 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_7241ca03-cda2-4383-8ac9-e3cd960db1aa"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS
</span></h1>
<p class="First">Topical corticosteroids are contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_6b4b91c4-7f7a-484f-89d0-8f84dcda3bd9"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS
</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_cd18a0b1-4b10-47d9-bb3c-dd6bcf2e29ea"></a><a name="section-6.1"></a><p></p>
<h2><span class="Bold">General
</span></h2>
<p class="First">Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestation of Cushing’s syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria in some patients.</p>
<p>Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, the addition of occlusive dressings, and dosage form.</p>
<p>Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.</p>
<p>Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.</p>
<p>Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See <a href="#LINK_fa0ecffd-6821-4af5-8b9b-14e62a43a772">PRECAUTIONS-Pediatric Use</a>).</p>
<p>Not for ophthalmic use. Severe irritation is possible if fluocinonide solution contacts the eye. If that should occur, immediate <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> of the eye with a large volume of water is recommended.</p>
<p>If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.</p>
<p>In the presence of dermatological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_4e358629-d16c-42d1-ad2c-4f311cfb30a7"></a><a name="section-6.2"></a><p></p>
<h2><span class="Bold">Information for Patient
</span></h2>
<p class="First">Patients using topical corticosteroids should receive the following information and instructions:</p>
<ol class="Arabic">
<li>This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes. If there is contact with the eyes and severe irritation occurs, immediately flush with a large volume of water.</li>
<li>Patients should be advised not to use this medication for any disorder other than for which it was prescribed.</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.</li>
<li>Patients should report any signs of local adverse reactions especially under occlusive dressing.</li>
<li>Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_16a2b129-dcbe-444b-9f0d-f8e9c2dc7799"></a><a name="section-6.3"></a><p></p>
<h2><span class="Bold">Laboratory Tests
</span></h2>
<p class="First">The following tests may be helpful in evaluating HPA axis suppression:</p>
<p>Urinary free cortisol test</p>
<p>ACTH stimulation test</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_6a97e013-8e2f-4db2-8317-93ff12fd524c"></a><a name="section-6.4"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility
</span></h2>
<p class="First">Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_8d003d24-d751-4b23-a2fc-18b5e3a5c7ec"></a><a name="section-6.5"></a><p></p>
<h2><span class="Bold">Pregnancy
</span></h2>
<p class="First">Pregnancy Category C. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of time.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_526abbea-a00f-42c2-99b0-56f92ff62829"></a><a name="section-6.6"></a><p></p>
<h2><span class="Bold">Nursing Mothers
</span></h2>
<p class="First">It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities <span class="Bold">not</span> likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_fa0ecffd-6821-4af5-8b9b-14e62a43a772"></a><a name="section-6.7"></a><p></p>
<h2><span class="Bold">Pediatric Use
</span></h2>
<p class="First"><span class="Bold">Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio.</span></p>
<p>Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing’s syndrome, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.</p>
<p>Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_151829c0-8230-45e0-926a-0ca1c616514c"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS
</span></h1>
<p class="First">The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence.</p>
<table>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td valign="top"> Burning</td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">Perioral dermatitis</span></td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">Itching</span></td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span></td>
</tr>
<tr>
<td valign="top"> Irritation</td>
<td valign="top"> Maceration of the skin</td>
</tr>
<tr>
<td valign="top"> Dryness</td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">Secondary infection</span></td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span></td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">Skin atrophy</span> </td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">Hypertrichosis</span></td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">Striae</span></td>
</tr>
<tr>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">Acneiform eruptions</span></td>
<td valign="top"> <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">Miliaria</span></td>
</tr>
<tr class="Last">
<td valign="top"> Hypopigmentation</td>
<td valign="top"> </td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_292f6ca6-58a2-4b57-85c8-cc66cf11169d"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">OVERDOSAGE
</span></h1>
<p class="First">Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See <a href="#LINK_6b4b91c4-7f7a-484f-89d0-8f84dcda3bd9">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_ce186c82-d576-4309-9d52-1febb1cb12a2"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION
</span></h1>
<p class="First">Fluocinonide topical solution 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition.</p>
<p>Occlusive dressings may be used for the management of <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span> or recalcitrant conditions.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_4b7a59e6-0cff-4d93-b02d-0cde95f186ea"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED
</span></h1>
<p class="First">Fluocinonide Topical Solution 0.05% is available in 60 mL plastic squeeze bottles.</p>
<p><span class="Bold">Store at 20-25°C (68-77°F) [See USP Controlled Room Temperature]. Avoid excessive heat, above 40°C (104°F).</span></p>
<p>Manufactured by</p>
<p>G&amp;W Laboratories, Inc.</p>
<p>111 Coolidge Street</p>
<p>South Plainfield, NJ 07080</p>
<p>Distributed by:</p>
<p>Actavis Mid Atlantic LLC</p>
<p>1877 Kawai Road</p>
<p>Lincolnton, NC 28092 USA</p>
<p>Rev. 08/12                                                                                                                   8-0322ACT1</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_c6a9eaed-c6ab-43b2-b2fa-13b004109c34"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
</span></h1>
<div class="Figure"><img alt="152f1db7-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=edb61362-d48f-487a-b15f-5ea3089d2f30&amp;name=fluocinonide-topical-solution-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLUOCINONIDE 		
					</strong><br><span class="contentTableReg">fluocinonide solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0472-0829</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLUOCINONIDE</strong> (FLUOCINONIDE) </td>
<td class="formItem">FLUOCINONIDE</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DIISOPROPYL ADIPATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0472-0829-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071535</td>
<td class="formItem">07/22/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Mid Atlantic LLC
							(809515898)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">G&amp;W Laboratories, Inc.</td>
<td class="formItem"></td>
<td class="formItem">001271188</td>
<td class="formItem">ANALYSIS(0472-0829, 0472-0829), MANUFACTURE(0472-0829, 0472-0829), PACK(0472-0829, 0472-0829)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>dd01fd90-413a-4e72-9c88-e858d90f0775</div>
<div>Set id: edb61362-d48f-487a-b15f-5ea3089d2f30</div>
<div>Version: 1</div>
<div>Effective Time: 20120817</div>
</div>
</div> <div class="DistributorName">Actavis Mid Atlantic LLC</div></p>
</body></html>
